KSKumari Shalini

Kumari Shalini

*This is an algorithmically generated author record based on publicly available information.

Kumari Shalini has a total of 4 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Synthesis and pharmacological screening of 4, 6-substituted di-(phenyl) pyrimidin-2-amines

    by Nitin Kumar, Sushma Drabu, Kumari Shalini

    A new series of 4, 6-substituted di-(phenyl) pyrimidin-2-amine (IIa–d) were synthesized by reacting chalcone derivatives with guanidine hydrochloride in the presence of dimethylformamide. The synthesized compounds were characterized by spectral analysis and were screened for anti-inflammatory activity. Two compounds 4-(4-nitrophenyl)-6-phenylpyrimidine-2-amine (IIa) and 4-(4-methoxyphenyl)-6-phenylpyrimidine-2-amine (IIb) showed highly significant reduction in oedema volume


  • Open Access

    Advances in synthetic approach to and antifungal activity of triazoles

    by Kumari Shalini, Nitin Kumar, Sushma Drabu, Pramod Kumar Sharma

    Several five membered ring systems, e.g., triazole, oxadiazole dithiazole and thiadiazole with three heteroatoms at symmetrical or asymmetrical positions have been studied because of their interesting pharmacological properties. In this article our emphasis is on synthetic development and pharmacological activity of the triazole moiety which exhibit a broad spectrum of pharmacological activity such as antifungal, antibacterial, anti-inflammatory and anticancer etc. Triazoles have increased our ability to treat many fungal infections, for example, candidiasis, cryptococcal meningitis, aspergillosis etc. However, mortality due to these infections even with antifungal therapy is still unacceptably high. Therefore, the development of new antifungal agents targeting specific fungal structures or functions is being actively pursued. Rapid developments in molecular mycology have led to a concentrated search for more target antifungals. Although we are entering a new era of antifungal therapy in which we will continue to be challenged by systemic fungal diseases, the options for treatment will have greatly expanded.